Search

everythinglearnresearchcommunity

for

Search:↓

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

CS12192 effectively treats alopecia areata with better safety than current options.

5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

A protein called sFRP4 from skin cells stops the development of pigment-producing cells in hair.

PDCD4 protein levels, affected by genetics and breastfeeding, may predict breast cancer treatment response.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Finasteride shows promise for preventing prostate cancer, but more research is needed.

Histone H4, released by cells exposed to colchicine, can cause hair loss by inhibiting cell growth and enzyme activity.

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

Rapamycin treatment helps with mitochondrial disease by reducing PKC levels.

Farudodstat can prevent hair follicle immune damage linked to alopecia areata.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.

JAK inhibitors offer new hope for treating severe alopecia areata.

Dutasteride effectively treats enlarged prostate with manageable side effects.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Tofacitinib treatment for hair loss may worsen acne.

EGFR inhibitors can cause skin issues, and managing these is important for treatment success.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

A man's rash caused by Finasteride improved after stopping the drug and starting new treatments.

Baricitinib reduces inflammation and improves cell health in premature aging cells.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.